Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Symbol: NASDAQ:SPHS
- CUSIP: N/A
- Web: www.sophiris.com
- Market Cap: $72.87 million
- Outstanding Shares: 30,111,000
- 50 Day Moving Avg: $2.57
- 200 Day Moving Avg: $2.71
- 52 Week Range: $0.87 - $8.55
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.84
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.48 per share
- Price / Book: 5.04
- EBIDTA: ($10,290,000.00)
- Return on Equity: -295.87%
- Return on Assets: -91.49%
- Current Ratio: 16.20%
- Quick Ratio: 16.20%
- Average Volume: 355,079 shs.
- Beta: 1.75
- Short Ratio: 5.55
Frequently Asked Questions for Sophiris Bio (NASDAQ:SPHS)
What is Sophiris Bio's stock symbol?
Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."
How were Sophiris Bio's earnings last quarter?
Sophiris Bio Inc (NASDAQ:SPHS) announced its quarterly earnings data on Monday, May, 15th. The company reported ($0.09) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.09) by $0.00. View Sophiris Bio's Earnings History.
Where is Sophiris Bio's stock going? Where will Sophiris Bio's stock price be in 2017?
6 equities research analysts have issued 1 year target prices for Sophiris Bio's shares. Their forecasts range from $5.00 to $8.00. On average, they expect Sophiris Bio's share price to reach $6.33 in the next twelve months. View Analyst Ratings for Sophiris Bio.
Are investors shorting Sophiris Bio?
Sophiris Bio saw a decline in short interest in the month of April. As of April 28th, there was short interest totalling 2,746,262 shares, a decline of 1.5% from the April 13th total of 2,788,009 shares. Based on an average daily volume of 187,126 shares, the short-interest ratio is presently 14.7 days.
Who are some of Sophiris Bio's key competitors?
Some companies that are related to Sophiris Bio include Agile Therapeutics (AGRX), pSivida Corp. (PSDV), Galectin Therapeutics (GALT), Lipocine (LPCN), Kalvista Pharmaceuticals (KALV), Innocoll Holdings PLC (INNL), Juniper Pharmaceuticals (JNP), SCYNEXIS (SCYX), Fibrocell Science (FCSC), Evoke Pharma (EVOK), Sonoma Pharmaceuticals (SNOA), Celator Pharmaceuticals (CPXX), NephroGenex (NRX), Parnell Pharmaceuticals Holdings Ltd (PARN) and Sagent Pharmaceuticals (SGNT).
Who owns Sophiris Bio stock?
Sophiris Bio's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.40%), Sabby Management LLC (1.14%), Palo Alto Investors LLC (0.82%) and Sofinnova Management VIII L.L.C. (0.66%). View Institutional Ownership Trends for Sophiris Bio.
Who sold Sophiris Bio stock? Who is selling Sophiris Bio stock?
Who bought Sophiris Bio stock? Who is buying Sophiris Bio stock?
How do I buy Sophiris Bio stock?
Shares of Sophiris Bio can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Sophiris Bio stock cost?
One share of Sophiris Bio stock can currently be purchased for approximately $2.42.
Earnings History for Sophiris Bio (NASDAQ:SPHS)Earnings History by Quarter for Sophiris Bio (NASDAQ:SPHS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Sophiris Bio (NASDAQ:SPHS)
2017 EPS Consensus Estimate: ($0.32)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Sophiris Bio (NASDAQ:SPHS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Sophiris Bio (NASDAQ:SPHS)
Insider Ownership Percentage: 5.90%Insider Trades by Quarter for Sophiris Bio (NASDAQ:SPHS)
Institutional Ownership Percentage: 5.99%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/15/2014||Boxer Capital, Llc||Major Shareholder||Sell||881,479||$0.61||$537,702.19|| |
|11/14/2014||Randall E Woods||Insider||Buy||3,000||$2.43||$7,290.00|| |
|9/19/2014||Gerald T Proehl||Director||Buy||10,000||$3.16||$31,600.00|| |
|7/10/2014||Randall E Woods||Insider||Buy||1,000||$2.65||$2,650.00|| |
|7/9/2014||Randall E Woods||Insider||Buy||1,000||$2.66||$2,660.00|| |
|6/6/2014||James L Heppell||Director||Sell||19,231||$2.59||$49,808.29|| |
|8/22/2013||Randall E Woods||CEO||Buy||2,500||$4.50||$11,250.00|| |
|8/20/2013||Peter T Slover||CFO||Buy||4,680||$4.25||$19,890.00|| |
|8/19/2013||Randall E Woods||CEO||Buy||10,000||$4.29||$42,900.00|| |
|8/16/2013||Boxer Capital, Llc||Major Shareholder||Buy||1,600,000||$5.00||$8,000,000.00|| |
Headline Trends for Sophiris Bio (NASDAQ:SPHS)
Latest Headlines for Sophiris Bio (NASDAQ:SPHS)
Sophiris Bio (SPHS) Chart for Tuesday, May, 23, 2017